- GAAP revenues grew 29.4% to
$18.2 millionin 2017, compared to $14.0 millionin 2016. GAAP revenues grew 23.3% to $3.3 millionin the fourth quarter of 2017, compared to $2.7 millionin the fourth quarter of 2016.
- Product shipments1 grew 16.2% to
$19.0 millionfor 2017, compared to $16.4 millionin 2016. Product shipments were $3.8 millionin the fourth quarter of 2017, compared to $5.2 millionin the fourth quarter of 2016.
- Gross margin increased significantly to 42.0% in 2017, compared to 32.2% in 2016. Gross margin increased to 46.0% in the fourth quarter of 2017, compared to 39.0% in the fourth quarter of 2016.
February 2018, the Company completed a comprehensive series of private placement financing and debt restructuring transactions, which generated approximately $27.3 millionof net proceeds and converted $45.0 millionof prior debt into equity.
“We begin 2018 healthier than ever,” said Dr.
“We were able to grow GAAP revenues almost 30% to a record
“We launched two new commercial products in 2017: Haven®, a sun protectant, and StargusTM, a biofungicide, addressing downy mildew and white mold, which complements our existing biofungicide Regalia. Both new products have performed exceptionally well in field trials and we look forward to expanding them across the NAFTA region. We believe StargusTM and its row crop counterpart, AmplitudeTM, open up important new market segments, such as eastern grapes and succulent and dry beans, peas and lentils. An additional significant 2017 milestone was first sales of another one of our active ingredients through our valued partner,
Dr. Marrone concluded: “Our recent financing and comprehensive debt restructuring transaction was truly transformative, providing us the tools we need to aggressively execute upon our business plan. We are concentrating on enhancing our sales and marketing organization and capabilities, increasing product awareness and educating growers.”
1See notes at the end of this release for additional information related to non-GAAP financial measures.
Recent Operational Highlights
- Launched two new Active Ingredients: Haven® sun protectant, and StargusTM biofungicide and our first turf product, ZeltoTM bioinsecticide/nematicide.
- Completed the development of MBI-014 (formerly 010), an organic bioherbicide, with
EPAsubmission planned in the near-term.
- Signed international distribution agreements for
Central America, Morocco& North Africa, Kenya, Mexicoand the Philippines.
- Finalized a distribution agreement with a large water treatment company,
Solenis LLC, for Zequanox.
- Implemented a strategy and focus to address grower demand of MBI products within the cannabis market through the creation of smaller pack sizes, hiring a cannabis segment sales specialist and utilizing
Amazonas a direct-to-consumer sales channel. Albaugh, LLC, a major agrichemical company, had a successful launch season with their BIOSTTM seed treatment containing a MBI microorganism, showing yield increases over the competitive standards. Seed treatment for row crops is a growth driver for MBI.
- As part of MBI’s collaboration with
Evogene, transgenic plants carrying genes from MBI’s novel insecticidal bacteria were developed and showed promising efficacy (100% kill) against pest caterpillars.
- Realized exceptional results from field trials in several countries around the globe, such as key banana, citrus and coffee diseases and pests. Particularly noteworthy are results from
Brazil, paving the way for registration of Grandevo, Venerate and Majestene.
Conference Call and Webcast
Management will host an investor conference call today at
Q4 2017 Conference Call and Webcast
International Dial-in: 1-323-794-2551
Conference ID: 3589839
Please dial in at least 10 minutes before the start of the call to ensure timely participation.
A playback of the call will be available through
Non-GAAP Financial Measures
The Company uses product shipments, which is not defined by, or presented in accordance with, generally accepted accounting principles (“GAAP”), to evaluate various aspects of its business. Product shipments is a non-GAAP financial measure and should be considered in addition to, not as a substitute for, product revenues reported in accordance with GAAP. Product shipments as used in this press release is defined as product revenues, plus related party product revenues, if any, plus the incremental amount of deferred revenues accrued during the applicable period. This calculation specifically excludes changes in deferred revenue related to license revenues and customer deposits and is intended to approximate the total value of products sold and under contract for sale in a given period. Product shipments, as defined by the Company, may not be comparable to similarly titled measures used by other companies. The Company’s management uses this non-GAAP financial measure in order to have comparable results to analyze sales performance from quarter to quarter. The Company has chosen to provide this supplemental information regarding its sales in a given period to investors to facilitate a meaningful evaluation of actual operating results on a comparable basis with historical results, including to track product adoption, and to assist investors in their valuation of the Company. In future periods, the calculation of product shipments may be different than in this release.
|THREE MONTHS ENDED
|(In Thousands)||(In Thousands)|
|Change in deferred product revenue(a)||574||2,583||1,086||2,651|
(a) Change in deferred product revenue is defined as the increase in the amount of deferred product revenues accrued during the applicable period, less prior deferred product revenues recognized during the applicable period, excluding the change in deferred revenue associated with license fees and customer deposits. For the three months ended
The use of product shipments has certain limitations. The Company's presentation of this non-GAAP financial measure may be different from the presentation used by other companies, and therefore comparability may be limited. We compensate for these limitations by providing the relevant disclosure of our product revenues, related party revenues, deferred revenues and other items both in our reconciliations to the historical GAAP financial measures and in our consolidated financial statements, all of which should be considered when evaluating our performance. Product shipments are used in addition to and in conjunction with results presented in accordance with GAAP, and should not be considered as an alternative to product revenues, deferred revenues, total revenues, operating income, or any other operating performance measure prescribed by GAAP, nor should these measures be relied upon to the exclusion of GAAP financial measures. Product shipments reflects an additional way of viewing our operations that we believe, when viewed with our GAAP results and the reconciliations to the corresponding historical GAAP financial measures, provides a more complete understanding of factors and trends affecting our business than could be obtained absent this disclosure. Management strongly encourages investors to review our financial information in its entirety, including the attached unaudited condensed consolidated financial statements, and not to rely on a single financial measure.
BIO WITH BITE.
Marrone Bio Innovations Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding the strength of the Company’s operations and financial position for 2018, anticipated cash resources for continued operations, sales of the Company’s products, enhancement of the Company’s marketing efforts, the impact of the Company’s portfolio development strategy, planned regulatory submissions and potential approvals, anticipated product launches, the potential benefits of the Company’s products, MBI’s efforts with respect to marketing in U.S. and international markets, and results of potential third-party collaborations. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the Company’s products, any difficulty in marketing MBI’s products in global markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties, and any inability to raise capital to fund operations and service the Company’s debt. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.
Marrone Bio Innovations Contacts:
Telephone: +1 (530) 750-2800
|MARRONE BIO INNOVATIONS, INC.|
|Consolidated Balance Sheets|
|(In Thousands, Except Par Value)|
|Cash and cash equivalents||$||786||$||9,609|
|Restricted cash, current portion||487||1,444|
|Deferred cost of product revenues||3,063||2,688|
|Prepaid expenses and other current assets||1,380||1,060|
|Total current assets||19,328||26,875|
|Property, plant and equipment, net||16,016||17,343|
|Restricted cash, less current portion||1,560||1,560|
|Liabilities and stockholders' deficit|
|Accrued interest due to related parties||1,622||1,618|
|Deferred revenue, current portion||6,193||5,647|
|Capital lease obligations, current portion||—||839|
|Debt, current portion||1,524||252|
|Total current liabilities||22,411||15,249|
|Deferred revenue, less current portion||2,046||1,787|
|Debt, less current portion||24,550||21,083|
|Debt due to related parties||37,822||36,667|
|Commitments and contingencies (Note 12)|
|Preferred stock: $0.00001 par value; 20,000 shares authorized and no shares issued or outstanding at December 31, 2017 and December 31, 2016||—||—|
|Common stock: $0.00001 par value; 250,000 shares authorized, 31,351 shares issued and outstanding as of December 31, 2017 and 24,661 as of December 31, 2016||—||—|
|Additional paid in capital||214,921||204,463|
|Total stockholders' deficit||(50,993||)||(30,184||)|
|Total liabilities and stockholders' deficit||$||37,123||$||45,983|
|See accompanying notes.|
|MARRONE BIO INNOVATIONS, INC.|
|Consolidated Statements of Operations|
|(In Thousands, Except Per Share Data)|
|Cost of product revenues, including cost of product revenues to related parties of $0, $0 and $254 for the years ended December 31, 2017, 2016 and 2015, respectively||10,528||9,522||9,256|
|Research, development and patent||11,012||9,670||13,500|
|Selling, general and administrative||20,101||18,510||26,502|
|Total operating expenses||31,113||28,180||40,002|
|Loss from operations||(23,474||)||(23,660||)||(39,457||)|
|Other income (expense):|
|Interest expense to related parties||(4,355||)||(4,361||)||(1,599||)|
|Change in estimated fair value of financial instruments||(96||)||—||—|
|Other income (expense), net||(36||)||(146||)||41|
|Total other expense, net||(7,793||)||(7,411||)||(4,271||)|
|Loss before income taxes||(31,267||)||(31,071||)||(43,728||)|
|Basic and diluted net loss per common share||$||(1.07||)||$||(1.26||)||$||(1.79||)|
|Weighted-average shares outstanding used in computing net loss per common share||29,235||24,617||24,469|
|See accompanying notes.|
|MARRONE BIO INNOVATIONS, INC.|
|Consolidated Statements of Cash Flows|
|YEAR ENDED DECEMBER 31,|
|Cash flows from operating activities|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Depreciation and amortization||2,044||2,235||3,510|
|Loss (gain) on disposal of equipment||363||135||(39||)|
|Share-based compensation and warrants issued for services||2,114||2,669||3,811|
|Non-cash interest expense||1,739||1,329||803|
|Chang in fair value of financial instruments||96||—||—|
|Net changes in operating assets and liabilities:|
|Prepaid Expenses and other assets||(354||)||189||142|
|Deferred cost of product revenues||(375||)||(1,092||)||201|
|Accrued and other liabilities||3,008||(219||)||(76||)|
|Accrued interest due to related parties||4||443||1,175|
|Deferred revenue from related parties||—||(168||)||(492||)|
|Customer refund liabilities||—||—||(1,044||)|
|Net cash used in operating activities||(21,056||)||(24,307||)||(36,174||)|
|Cash flows from investing activities|
|Purchases of property, plant and equipment||(849||)||(209||)||(1,653||)|
|Proceeds from the sale of equipment||—||—||7|
|Sale of property, plant and equipment||35||—||—|
|Net cash used in investing activities||(814||)||(209||)||(1,646||)|
|Cash flows from financing activities|
|Proceeds from issuance of common stock, net of offering costs||8,188||—||—|
|Proceeds from issuance of debt||4,000||—||—|
|Proceeds from issuance of debt due to related parties, net of financing costs||—||—||39,698|
|Proceeds from secured borrowings||16,228||—||—|
|Reductions in secured borrowings||(14,952||)||—||—|
|Repayment of debt||(756||)||(260||)||(435||)|
|Repayment of capital leases||(420||)||(821||)||(1,983||)|
|Change in restricted cash||957||15,412||(15,000||)|
|Exercise of stock options||17||31||54|
|Net cash provided by financing activities||13,047||14,287||22,334|
|Net decrease in cash and cash equivalents||(8,823||)||(10,229||)||(15,486||)|
|Cash and cash equivalents, beginning of period||9,609||19,838||35,324|
|Cash and cash equivalents, end of period||$||786||$||9,609||$||19,838|
|Supplemental disclosure of cash flow information|
|Cash paid for interest, net of capitalized interest of $0, $0, and $4 and for the years ended December 31, 2017, 2016 and 2015, respectively||$||5,926||$||5,550||$||2,297|
|Supplemental disclosure of non-cash investing and financing activities|
|Property, plant and equipment included in accounts payable and accrued liabilities||$||245||$||21||$||499|
|Equipment acquired under capital leases||$||—||$||1,586||$||787|
Source: Marrone Bio Innovations